Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
- Combining Second-Line Targeted Therapies for Advanced Kidney Cancer
(Posted: 06/14/2011) - The goal of this clinical trial is to determine whether using everolimus and bevacizumab in combination will improve the overall survival of patients with renal cell carcinoma (kidney cancer) whose disease has progressed on approved tyrosine kinase inhibitors.
- Metformin to Treat Early-Stage Breast Cancer
(Posted: 05/31/2011) - In this trial, nondiabetic women or men younger than age 75 who have been diagnosed with early-stage breast cancer within the previous 12 months and who have undergone surgery to remove their tumor will be randomly assigned to take metformin or placebo pills twice a day for 5 years.
- Lenalidomide and Radiation for Children with Brain Cancers
(Posted: 05/17/2011) - In this trial, patients up to age 18 who are newly diagnosed with diffuse intrinsic pontine gliomas (DIPG) or who have other high-grade gliomas that could not be completely resected will undergo radiation therapy and receive oral lenalidomide at increasing doses daily for 6 weeks, followed by lenalidomide alone.
- Testing Dose-Dense Paclitaxel for Ovarian and Related Cancers
(Posted: 05/03/2011) - In this trial, women with stage III or IV ovarian epithelial, fallopian tube, or primary peritoneal cancer will be randomly assigned to receive either standard or dose-dense paclitaxel in addition to standard carboplatin (given once every 3 weeks) and optional bevacizumab.
- Inhibiting Tumor Angiogenesis in Metastatic Hormone-Refractory Prostate Cancer
(Posted: 04/05/2011) - In this NIH Clinical Center study, researchers will test whether treatment with a novel monoclonal antibody, TRC105, that targets a protein highly expressed on the surface of tumor blood vessels improves the outcome of men with metastatic castration-resistant prostate cancer.